M. Hery, T. Delozier, A. Ramaioli, J. P. Julien, B. De-lafontan et al., Natural history of node-negative breast cancer: are conventional prognostic factors predictors of time to relapse, Breast, vol.11, pp.442-450, 2002.

M. Sundquist, S. Thorstenson, L. Brudin, S. Wingren, and B. Nordenskjold, Incidence and prognosis in early onset breast cancer, Breast, vol.11, pp.30-35, 2002.

, Early Breast Cancer Trialists' Collaborative Group. Multi-agent chemotherapy for early breast cancer, Cochrane Database Syst Rev, vol.000487, 2002.

, Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group, Lancet, vol.352, pp.930-972, 1998.

, Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group, Lancet, vol.351, pp.1451-67, 1998.

, Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials, Lancet, vol.365, pp.1687-717, 2005.

K. Albain, W. Barlow, and F. O'malley, Concurrent (CAFT) versus sequential (CAF-T) chemohormonal therapy (cyclophosphamide, doxorubicin, 5-fluorouracil, tamoxifen) versus T alone for postmenopausal, node-positive, estrogen (ER) and/or progesterone (PgR) receptor-positive breast cancer: mature outcomes and new biologic correlates on phase III intergroup trial 0100 (SWOG-8814), San Antonio Breast Cancer Symposium, p.37, 2004.

B. Fisher, J. H. Jeong, J. Bryant, S. Anderson, J. Dignam et al., Treatment of lymph-node-negative, oestrogen-receptorpositive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials, Lancet, vol.364, pp.858-68, 2004.

, Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial, J Natl Cancer Inst, vol.94, pp.1054-65, 2002.

D. F. Hayes, A. D. Thor, L. G. Dressler, D. Weaver, S. Edgerton et al., HER2 and response to paclitaxel in node-positive breast cancer, N Engl J Med, vol.357, pp.1496-506, 2007.

D. A. Berry, C. Cirrincione, I. C. Henderson, M. L. Citron, D. R. Budman et al., Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer, JAMA, vol.295, pp.1658-67, 2006.

, Cancer du sein infiltrant non métastatique -Questions d'actualité. Collection Avis & Recommandations, 2012.

D. F. Hayes, R. C. Bast, C. E. Desch, F. Hjr, N. E. Kemeny et al., Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers, J Natl Cancer Inst, vol.88, pp.1456-66, 1996.

S. M. Teutsch, L. A. Bradley, G. E. Palomaki, J. E. Haddow, M. Piper et al., The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP Working Group, Genet Med, vol.11, pp.3-14, 2009.

C. M. Sturgeon, B. R. Hoffman, D. W. Chan, . Ch'ng, . Sl et al., National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in clinical practice: quality requirements, Clin Chem, vol.54, pp.1-1, 2008.

D. G. Altman, L. M. Mcshane, W. Sauerbrei, and S. E. Taube, Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration, BMC Med, vol.10, p.51, 2012.

R. M. Simon, S. Paik, and D. F. Hayes, Use of archived specimens in evaluation of prognostic and predictive biomarkers, J Natl Cancer Inst, vol.101, pp.1446-52, 2009.

S. Gluck, A. Y. Yip, and E. L. Ng, Can we replace the microscope with microarrays for diagnosis, prognosis and treatment of early breast cancer?, Expert Opin Ther Targets, vol.16, pp.17-22, 2012.

F. Janicke, A. Prechtl, C. Thomssen, N. Harbeck, C. Meisner et al., Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1, J Natl Cancer Inst, vol.93, pp.913-933, 2001.

N. Harbeck, M. Schmitt, C. Meisner, C. Friedel, M. Untch et al., )-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients, American Society of Clinical Oncology, vol.49, pp.1825-1860, 2013.

M. P. Look, W. L. Van-putten, M. J. Duffy, N. Harbeck, I. J. Christensen et al., Pooled analysis of prognostic impact of urokinasetype plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients, J Natl Cancer Inst, vol.94, pp.116-144, 2002.

C. Mazouni, P. Bonnier, R. S. Martin, and P. M. , A nomogram predicting the probability of primary breast cancer survival at 2-and 5-years using pathological and biological tumor parameters, J Surg Oncol, vol.103, pp.746-50, 2011.

S. Jelisavac-cosic, M. Sirotkovic-skerlev, A. Kulic, J. Jakic-razumovic, Z. Kovac et al., Prognostic significance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor (PAI-1) in patients with primary invasive ductal breast carcinoma -a 7.5-year follow-up study, Tumori, vol.97, pp.532-541, 2011.

C. Mazouni, S. Romain, P. Bonnier, L. Ouafik, and P. M. Martin, Prognostic significance of tumorrelated proteases as a function of the estrogen receptor status, Cancer Biol Ther, vol.11, pp.277-83, 2011.
URL : https://hal.archives-ouvertes.fr/hal-01827405

N. Harbeck, M. Schmitt, R. E. Kates, M. Kiechle, I. Zemzoum et al., Clinical utility of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 determination in primary breast cancer tissue for individualized therapy concepts, Clin Breast Cancer, vol.3, pp.196-200, 2002.

N. Harbeck, R. E. Kates, M. Schmitt, K. Gauger, M. Kiechle et al., Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer, Clin Breast Cancer, vol.5, pp.348-52, 2004.

S. Borstnar, A. Sadikov, B. Mozina, and T. Cufer, High levels of uPA and PAI-1 predict a good response to anthracyclines, Breast Cancer Res Treat, vol.121, pp.615-639, 2010.
URL : https://hal.archives-ouvertes.fr/hal-00612980

S. Haas, T. W. Park, J. C. Hahne, and H. P. Fischer, Influence of preoperative core biopsies on uPA/PAI-1 expression in breast cancer tissue, Virchows Arch, vol.452, pp.277-83, 2008.

C. G. Sweep, J. Geurts-moespot, N. Grebenschikov, J. H. De-witte, J. J. Heuvel et al., External quality assessment of trans-European multicentre antigen determinations (enzymelinked immunosorbent assay) of urokinasetype plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts, Br J Cancer, vol.78, pp.1434-1475, 1998.

I. D. Witzel, K. Milde-langosch, R. M. Wirtz, C. Roth, M. Ihnen et al., Comparison of microarray-based RNA expression with ELISAbased protein determination of HER2, uPA and PAI-1 in tumour tissue of patients with breast cancer and relation to outcome, J Cancer Res Clin Oncol, vol.136, pp.1709-1727, 2010.

K. Malinowsky, C. Bollner, S. Hipp, D. Berg, M. Schmitt et al., UPA and PAI-1 analysis from fixed tissues -new perspectives for a known set of predictive markers, Curr Med Chem, vol.17, pp.4370-4377, 2010.

C. Thomssen, N. Harbeck, J. Dittmer, S. R. Abraha-spaeth, N. Papendick et al., Feasibility of measuring the prognostic factors uPA and PAI-1 in core needle biopsy breast cancer specimens, J Natl Cancer Inst, vol.101, pp.1028-1037, 2009.

S. Paik, S. Shak, G. Tang, C. Kim, J. Baker et al., A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer, N Engl J Med, vol.351, pp.2817-2843, 2004.

M. Toi, H. Iwata, T. Yamanaka, N. Masuda, S. Ohno et al., Clinical significance of the 21-gene signature (Oncotype DX) in hormone receptor-positive early stage primary breast cancer in the Japanese population, Cancer, vol.116, pp.3112-3120, 2010.

M. Dowsett, J. Cuzick, C. Wale, J. Forbes, E. A. Mallon et al., Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study, J Clin Oncol, vol.28, pp.1829-1863, 2010.

B. Fisher, J. Costantino, C. Redmond, R. Poisson, D. Bowman et al., A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors, N Engl J Med, vol.320, pp.479-84, 1989.

, Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis, Ont Health Technol Assess Ser, vol.10, pp.1-57, 2010.

H. A. Azim, S. Michiels, F. Zagouri, S. Delaloge, M. Filipits et al., Utility of prognostic genomic tests in breast cancer practice, Ann Oncol, vol.24, pp.647-54, 2013.

C. M. Sturgeon and E. Diamandis, Use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers, 2009.

. Ago-breast-committee, Prognostic and predictive factors. Diagnosis and treatment of patients with primary and metastatic breast cancer, 2012.

B. Weigelt, J. S. Reis-filho, and C. Swanton, Genomic analyses to select patients for adjuvant chemotherapy: trials and tribulations, Ann Oncol, vol.23, pp.211-219, 2012.

J. Hornberger, M. D. Alvarado, C. Rebecca, H. R. Gutierrez, T. M. Yu et al., Clinical validity/utility, change in practice patterns, and economic implications of risk stratifiers to predict outcomes for early-stage breast cancer: a systematic review, J Natl Cancer Inst, vol.104, pp.1068-79, 2012.

P. G. Febbo, M. Ladanyi, K. D. Aldape, D. Marzo, A. M. Hammond et al., NCCN Task Force report: evaluating the clinical utility of tumor markers in oncology, J Natl Compr Canc Netw, vol.9, pp.1-32, 2011.

E. P. Mamounas, G. Tang, B. Fisher, S. Paik, S. Shak et al., Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20

, J Clin Oncol, vol.28, pp.1677-83, 2010.

K. S. Albain, W. E. Barlow, S. Shak, G. N. Hortobagyi, R. B. Livingston et al., Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial, Lancet Oncol, vol.11, pp.55-65, 2010.

K. Yorozuya, T. Takeuchi, M. Yoshida, Y. Mouri, J. Kousaka et al., Evaluation of Oncotype DX Recurrence Score as a prognostic factor in Japanese women with estrogen receptor-positive, node-negative primary Stage I or IIA breast cancer, J Cancer Res Clin Oncol, vol.136, pp.939-983, 2010.

S. Paik, G. Tang, S. Shak, C. Kim, J. Baker et al., Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer, J Clin Oncol, vol.24, pp.3726-3760, 2006.

M. Kaufmann, L. Pusztai, B. Expert, and P. M. , Use of standard markers and incorporation of molecular markers into breast cancer therapy: consensus recommendations from an International Expert Panel, Cancer, vol.117, pp.1575-82, 2011.

, Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: can tumor gene expression profiling improve outcomes in patients with breast cancer, Gen Med, vol.11, pp.66-73, 2009.

S. Akashi-tanaka, C. Shimizu, M. Ando, T. Shibata, N. Katsumata et al., 21-Gene expression profile assay on core needle biopsies predicts responses to neoadjuvant endocrine therapy in breast cancer patients, Breast, vol.18, pp.171-175, 2009.

D. J. Dabbs, M. E. Klein, S. K. Mohsin, R. R. Tubbs, Y. Shuai et al., High false-negative rate of HER2 quantitative reverse transcription polymerase chain reaction of the Oncotype DX test: an independent quality assurance study, J Clin Oncol, vol.29, pp.4279-85, 2011.

F. L. Baehner, N. Achacoso, T. Maddala, S. Shak, Q. Cpjr et al., Human epidermal growth factor receptor 2 assessment in a case-control study: comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories, J Clin Oncol, vol.28, pp.4300-4306, 2010.

S. M. O'connor, S. Beriwal, D. J. Dabbs, and R. Bhargava, Concordance between semiquantitative immunohistochemical assay and oncotype DX RT-PCR assay for estrogen and progesterone receptors, Appl Immunohistochem Mol Morphol, vol.18, pp.268-72, 2010.

B. Sun, F. Zhang, S. K. Wu, X. Guo, L. L. Zhang et al., Gene expression profiling for breast cancer prognosis in Chinese populations, Breast, vol.17, pp.172-181, 2011.

M. B. Flanagan, D. J. Dabbs, A. M. Brufsky, S. Beriwal, and R. Bhargava, Histopathologic variables predict Oncotype DX recurrence score, Mod Pathol, vol.21, pp.1255-61, 2008.

K. Gwin, M. Pinto, and F. A. Tavassoli, Complementary value of the Ki-67 proliferation index to the oncotype DX recurrence score, Int J Surg Pathol, vol.17, pp.303-313, 2009.

J. Auerbach, M. Kim, and S. Fineberg, Can features evaluated in the routine pathologic assessment of lymph node-negative estrogen receptor-positive stage I or II invasive breast cancer be used to predict the Oncotype DX recurrence score?, Arch Pathol Lab Med, vol.134, pp.1697-701, 2010.

C. M. Kelly, S. Krishnamurthy, G. Bianchini, J. K. Litton, A. M. Gonzalez-angulo et al., Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers, Cancer, vol.116, pp.5161-5168, 2010.

S. Sahebjam, R. Aloyz, D. Pilavdzic, M. L. Brisson, C. Ferrario et al., Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score, Br J Cancer, vol.105, pp.1342-1347, 2011.

P. Tang, J. Wang, D. G. Hicks, X. Wang, L. Schiffhauer et al., A lower Allred score for progesterone receptor is strongly associated with a higher recurrence score of 21-gene assay in breast cancer, Cancer Invest, vol.28, pp.978-82, 2010.

D. J. Williams, C. Cohen, M. Darrow, A. J. Page, B. Chastain et al., Proliferation (Ki-67 and phosphohistone H3) and oncotype DX recurrence score in estrogen receptorpositive breast cancer, Appl Immunohistochem Mol Morphol, vol.19, pp.431-437, 2011.

J. Cuzick, M. Dowsett, S. Pineda, C. Wale, J. Salter et al., Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer, J Clin Oncol, vol.29, pp.4273-4281, 2011.

M. Cronin, C. Sangli, M. L. Liu, M. Pho, D. Dutta et al., Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer, Clin Chem, vol.53, pp.1084-91, 2007.

E. Espinosa, I. Sanchez-navarro, A. Gamez-pozo, A. P. Marin, D. Hardisson et al., Comparison of prognostic gene profiles using qRT-PCR in paraffin samples: a retrospective study in patients with early breast cancer, PLoS ONE, vol.4, p.5911, 2009.

K. J. Kao, K. M. Chang, H. C. Hsu, and A. T. Huang, Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes: implications for treatment optimization, BMC Cancer, vol.11143, 2011.

L. J. Van't-veer, H. Dai, M. J. Van-de-vijver, Y. D. He, A. A. Hart et al., Gene expression profiling predicts clinical outcome of breast cancer, Nature, vol.415, pp.530-536, 2002.

M. J. Van-de-vijver, Y. D. He, L. J. Van't-veer, H. Dai, A. A. Hart et al., A gene-expression signature as a predictor of survival in breast cancer, N Engl J Med, vol.347, pp.1999-2009, 2002.

M. Buyse, S. Loi, L. Van't-veer, G. Viale, M. Delorenzi et al., Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer, J Natl Cancer Inst, vol.98, pp.1183-92, 2006.

J. M. Bueno-de-mesquita, S. C. Linn, R. Keijzer, J. Wesseling, D. S. Nuyten et al., Validation of 70-gene prognosis signature in node-negative breast cancer, Breast Cancer Res Treat, vol.117, pp.483-95, 2009.
URL : https://hal.archives-ouvertes.fr/hal-00478268

M. Knauer, F. Cardoso, J. Wesseling, P. L. Bedard, S. C. Linn et al., Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature, Br J Cancer, vol.103, pp.1788-93, 2010.

J. M. Bueno-de-mesquita, G. S. Sonke, M. J. Van-de-vijver, and S. C. Linn, Additional value and potential use of the 70-gene prognosis signature in node-negative breast cancer in daily clinical practice, Ann Oncol, vol.22, pp.2021-2051, 2011.

G. Kunz, Use of a genomic test (Mamma-Print TM ) in daily clinical practice to assist in risk stratification of young breast cancer patients, Arch Gynecol Obstet, vol.283, pp.597-602, 2011.

S. Mook, M. K. Schmidt, G. Viale, G. Pruneri, I. Eekhout et al., The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study, Breast Cancer Res Treat, vol.116, pp.295-302, 2009.
URL : https://hal.archives-ouvertes.fr/hal-00478252

S. Mook, M. Knauer, J. M. Bueno-de-mesquita, V. P. Retel, J. Wesseling et al., Metastatic potential of T1 breast cancer can be predicted by the 70-gene MammaPrint signature, Ann Surg Oncol, vol.17, pp.1406-1419, 2010.

S. Mook, M. K. Schmidt, B. Weigelt, B. Kreike, I. Eekhout et al., The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age, Ann Oncol, vol.21, pp.717-739, 2010.

M. Knauer, S. Mook, E. J. Rutgers, R. A. Bender, M. Hauptmann et al., The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer, Breast Cancer Res Treat, vol.120, pp.655-61, 2010.
URL : https://hal.archives-ouvertes.fr/hal-00535448

M. E. Straver, A. M. Glas, J. Hannemann, J. Wesseling, M. J. Van-de-vijver et al., The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer, Breast Cancer Res Treat, vol.119, pp.551-559, 2010.
URL : https://hal.archives-ouvertes.fr/hal-00535339

S. Mook, H. Bonnefoi, G. Pruneri, D. Larsimont, J. Jaskiewicz et al., Daily clinical practice of fresh tumour tissue freezing and gene expression profiling; logistics pilot study preceding the MINDACT trial, Eur J Cancer, vol.45, pp.1201-1209, 2009.

C. E. Bacchi, F. Prisco, F. M. Carvalho, E. B. Ojopi, and E. D. Saad, Potential economic impact of the 21-gene expression assay on the treatment of breast cancer in Brazil, Rev Assoc Med Bras, vol.56, pp.186-91, 2010.

E. Chen, K. B. Tong, and J. L. Malin, Cost-effectiveness of 70-gene MammaPrint signature in nodenegative breast cancer, Am J Manag Care, vol.16, pp.333-375, 2010.

P. S. Hall, C. Mccabe, R. C. Stein, and D. Cameron, Economic evaluation of genomic test-directed chemotherapy for early-stage lymph nodepositive breast cancer, J Natl Cancer Inst, vol.104, pp.56-66, 2012.

J. Hornberger, L. E. Cosler, and G. H. Lyman, Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer, Am J Manag Care, vol.11, pp.313-337, 2005.

J. Hornberger, R. Chien, K. Krebs, and L. Hochheiser, US insurance program's experience with a multigene assay for early-stage breast cancer, Am J Manag Care, vol.17, pp.194-202, 2011.

S. H. Klang, A. Hammerman, N. Liebermann, N. Efrat, J. Doberne et al., Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization, Value Health, vol.13, pp.381-388, 2010.

M. Kondo, S. L. Hoshi, H. Ishiguro, H. Yoshibayashi, and M. Toi, Economic evaluation of 21-gene reverse transcriptase-polymerase chain reaction assay in lymph-node-negative, estrogenreceptor-positive, early-stage breast cancer in Japan, Breast Cancer Res Treat, vol.112, pp.175-87, 2008.

M. Kondo, S. L. Hoshi, T. Yamanaka, H. Ishiguro, and M. Toi, Economic evaluation of the 21-gene signature (Oncotype DX) in lymph nodenegative/positive, hormone receptor-positive early-stage breast cancer based on Japanese validation study (JBCRG-TR03), Breast Cancer Res Treat, vol.127, pp.739-788, 2011.

M. Kondo, S. L. Hoshi, H. Ishiguro, and M. Toi, Economic evaluation of the 70-gene prognosis-signature (MammaPrint ® ) in hormone receptor-positive, lymph node-negative, human epidermal growth factor receptor type 2-negative early stage breast cancer in Japan, Breast Cancer Res Treat, vol.133, pp.759-68, 2012.

N. W. Lamond, C. Skedgel, D. Rayson, L. Lethbridge, and T. Younis, Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer, Breast Cancer Res Treat, vol.133, pp.1115-1138, 2012.

G. H. Lyman, L. E. Cosler, N. M. Kuderer, and J. Hornberger, Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies, Cancer, vol.109, pp.1011-1019, 2007.

N. Oestreicher, S. D. Ramsey, H. M. Linden, J. S. Mccune, L. J. Van't-veer et al., Gene expression profiling and breast cancer care: what are the potential benefits and policy implications, Gen Med, vol.7, pp.380-389, 2005.

V. P. Retel, M. A. Joore, M. Knauer, S. C. Linn, M. Hauptmann et al., Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer, Eur J Cancer, vol.46, pp.1382-91, 2010.

V. P. Retel, M. A. Joore, and W. H. Van-harten, Head-tohead comparison of the 70-gene signature versus the 21-gene assay: cost-effectiveness and the effect of compliance, Breast Cancer Res Treat, vol.131, pp.627-663, 2012.

D. T. Tsoi, M. Inoue, C. M. Kelly, S. Verma, and K. I. Pritchard, Cost-effectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancer, Oncologist, vol.15, pp.457-65, 2010.

B. F. Vanderlaan, M. S. Broder, E. Y. Chang, R. Oratz, and T. G. Bentley, Cost-effectiveness of 21-gene assay in node-positive, early-stage breast cancer, Am J Manag Care, vol.17, pp.455-64, 2011.

A. L. Vataire, E. Laas, S. Aballea, J. Gligorov, R. Rouzier et al., Cost-effectiveness of a chemotherapy predictive test] Analyse coûtefficacité d'un test prédictif de la chimiothérapie dans le cancer du sein (Oncotype DX ® ) en France, Bull Cancer, vol.99, pp.907-921, 2012.

M. Yang, S. Rajan, and A. M. Issa, Cost effectiveness of gene expression profiling for early stage breast cancer: a decision-analytic model, Cancer, vol.118, pp.5163-70, 2012.

S. Ward, A. Scope, R. Rafia, A. Pandor, S. Harnan et al., Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management. ScHARR University of Sheffield, 2011.